Caribou Biosciences Advances CRISPR-Edited CAR-T Therapy in Lymphoma Study

Caribou Biosciences, Inc. ((CRBU)) announced an update on their ongoing clinical study.

Caribou Biosciences, Inc. is conducting a Phase 1 clinical trial titled ‘A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)’. The study aims to evaluate the safety, emerging efficacy, pharmacokinetics, and immunogenicity of CB-010 in adults with relapsed or refractory B cell non-Hodgkin lymphoma. This study is significant as it explores innovative gene-editing technology to potentially offer new treatment options for patients with limited alternatives.

The intervention being tested is CB-010, a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19. It is administered following lymphodepletion with chemotherapy drugs Cyclophosphamide and Fludarabine, aiming to treat relapsed or refractory non-Hodgkin lymphoma.

The study employs a non-randomized, single-group intervention model with no masking. It consists of two parts: a dose-escalation phase to determine the optimal dose, followed by an expansion phase where patients receive the determined dose. The primary purpose of the study is treatment-focused.

The study began on November 16, 2020, with primary completion expected in 2025. The latest update was submitted on March 21, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results.

This clinical update could influence Caribou Biosciences’ stock performance positively, as successful outcomes may enhance investor confidence and position the company as a leader in CRISPR-based therapies. The study’s progress is also relevant in the context of competitive advancements in the CAR-T cell therapy space.

The study is ongoing, with further details available on the ClinicalTrials portal.